Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways

Blood

Volumn 117, Issue 23, 2011, Pages 6392-6403

  Chen, Yang ^a,b   Wang, Shan ^a,b   Lu, Xinan ^a,b   Zhang, Haoran ^a,b   Fu, Yan ^a,b   Luo, Yongzhang ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b Beijing Key Laboratory for Protein Therapeutics   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CAVEOLIN 1; CHLORPROMAZINE; CHOLESTEROL; CLATHRIN; ENDOSTATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEOLIN; NYSTATIN; SMALL INTERFERING RNA; TRANSFERRIN; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAVEOLA; CELL MIGRATION; CELL STRUCTURE; COATED VESICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; ENDOCYTOSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTERNALIZATION; LIPID RAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

EID: 79959443619     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-322867     Document Type: Article

References (50)

1. Le Roy C, Wrana JL. Clathrin- and non-clathrinmediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6(2):112-126. (Pubitemid 40215807)
2. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185-194.
3. Anderson RG. The caveolae membrane system. Annu Rev Biochem. 1998;67:199-225. (Pubitemid 28411129)
4. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1(1):31-39.
5. Okamoto Y, Ninomiya H, Miwa S, Masaki T. Cholesterol oxidation switches the internalization pathway of endothelin receptor type A from caveolae to clathrin-coated pits in Chinese hamster ovary cells. J Biol Chem. 2000;275(9):6439-6446. (Pubitemid 30129941)
6. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003;5(5):410-421. (Pubitemid 36592263)
7. Stoddart A, Jackson AP, Brodsky FM. Plasticity of B cell receptor internalization upon conditional depletion of clathrin. Mol Biol Cell. 2005;16(5): 2339-2348. (Pubitemid 40632216)
8. Taylor DR, Watt NT, Perera WS, Hooper NM. Assigning functions to distinct regions of the Nterminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci. 2005;118(Pt 21):5141-5153. (Pubitemid 41672444)
9. Hartung A, Bitton-Worms K, Rechtman MM, et al. Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol. 2006;26(20):7791-7805. (Pubitemid 44547724)
10. Masuyama N, Kuronita T, Tanaka R, et al. HM1.24 Is Internalized from Lipid Rafts by Clathrin-mediated Endocytosis through Interaction with alpha-Adaptin. J Biol Chem. 2009; 284(23):15927-15941.
11. Pellinen T, Tuomi S, Arjonen A, et al. Integrin trafficking regulated by Rab21 is necessary for cytokinesis. Dev Cell. 2008;15(3):371-385.
12. Shi F, Sottile J. Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnover. J Cell Sci. 2008;121(pt 14): 2360-2371.
13. Caswell PT, Vadrevu S, Norman JC. Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol. 2009;10(12):843-853.
14. Migalovich HS, Kalchenko V, Nevo N, Meir G, Kohen F, Neeman M. Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and nearinfrared imaging of bifunctional contrast media. Cancer Res. 2009;69(13):5610-5617.
15. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010;17(6):574-583.
16. OReilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285. (Pubitemid 28015876)
17. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594-607. (Pubitemid 43290336)
18. Dixelius J, Larsson H, Sasaki T, et al. Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000;95(11):3403-3411. (Pubitemid 30428470)
19. MacDonald NJ, Shivers WY, Narum DL, et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem. 2001;276(27):25190-25196.
20. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 2001; 98(3):1024-1029. (Pubitemid 32121180)
21. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell. 2001;7(4):811-822. (Pubitemid 32436441)
22. Sasaki T, Fukai N, Mann K, GohringW, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 1998;17(15):4249-4256. (Pubitemid 28362615)
23. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res. 2000; 60(19):5410-5413.
24. Shi HB, Huang YJ, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood. 2007;110(8): 2899-2906. (Pubitemid 350006943)
25. Sudhakar A, Sugimoto H, Yang CQ, Lively J, Zeisberg M, Kalluri R. Human tumstatin land human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A. 2003; 100(8):4766-4771. (Pubitemid 36457804)
26. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha(5)beta(1) and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002;62(19):5580-5589.
27. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via downregulation of RhoA activity. J Biol Chem. 2003; 278(39):37895-37901. (Pubitemid 37175319)
28. Zhang AY, Yi F, Zhang G, Gulbins E, Li P-L. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension. 2006;47(1):74-80. (Pubitemid 43177818)
29. Jin S, Zhang Y, Yi F, Li P-L. Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2008;28(3):485-490.
30. Benmerah A, Bayrou M, Cerf-Bensussan N, Dautry-Varsat A. Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J Cell Sci. 1999; 112(Pt 9):1303-1311. (Pubitemid 29243453)
31. He Y, Chang G, Zhan S, Song X, Wang X, Luo Y. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem Biophys Res Commun. 2008; 370(3):489-494.
32. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99(6):683-690. (Pubitemid 23002027)
33. Liu X, Wang D, Liu F, Bai J. Principal component analysis of dynamic fluorescence diffuse optical tomography images. Opt Express. 2010;18(6): 6300-6314.
34. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68(4):673-682.
35. Puri V, Watanabe R, Singh RD, et al. Clathrindependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways. J Cell Biol. 2001; 154(3):535-547. (Pubitemid 34286160)
36. Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood. 2009;114(9):1987- 1998.
37. Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood. 2006;107(9):3564-3571.
38. Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem. 2002;277(40): 37492-37502.
39. Legrand D, Vigie K, Said EA, et al. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem. 2004;271(2):303-317. (Pubitemid 38130458)
40. Wang LH, Rothberg KG, Anderson RG. Misassembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol. 1993;123(5):1107-1117. (Pubitemid 23352421)
41. Riezman H,Woodman PG, van Meer G, Marsh M. Molecular mechanisms of endocytosis. Cell. 1997;91(6):731-738. (Pubitemid 28007730)
42. Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factormediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277(31):27872-27879. (Pubitemid 34966733)
43. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem. 1998; 273(33):21099-21104. (Pubitemid 28385396)
44. Citrin D, Lee AK, Scott T, et al. In vivo tumor imaging in mice with near-infrared labeled endostatin. Mol Cancer Ther. 2004;3(4):481-488. (Pubitemid 39193726)
45. Sachais BS, Kuo A, Nassar T, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood. 2002;99(10):3613-3622. (Pubitemid 34534530)
46. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized lowdensity lipoprotein to vascular wall cells. J Biol Chem. 2003;278(8):6187-6193. (Pubitemid 36800873)
47. Chen H, Sottile J, Strickland DK, Mosher DF. Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and low-density-lipoprotein receptor-related protein: localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1. Biochem J. 1996;318(Pt 3): 959-963. (Pubitemid 26320965)
48. Pilch J, Franzin CM, Knowles LM, Ferrer FJ, Marassi FM, Ruoslahti E. The anti-angiogenic peptide anginex disrupts the cell membrane. J Mol Biol. 2006;356(4):876-885. (Pubitemid 43145943)
49. Yang DJ, Kim KD, Schechter NR, et al. Assessment of antiangiogenic effect using Tc-99m-ECendostatin. Cancer Biother Radiopharm. 2002; 17(2):233-246. (Pubitemid 34507423)
50. Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci. 2003;6(1): 67-83. (Pubitemid 37207242)